智飞生物：公司参股企业重庆智睿投资有限公司投资孵化了重庆精准生物技术有限公司

Group 1 - The core point of the article is the approval of a new drug, Pugilone Injection, by Chongqing Precision Biotechnology, which is expected to have a significant impact on the company and its investors [2] - Zhifei Biological, a company listed on the Shenzhen Stock Exchange, has a stake in Chongqing Zhihui Investment Co., which incubated Chongqing Precision Biotechnology [2] - The new drug is classified as a national Class 1 biological new drug, indicating its importance and potential in the market [2]